GLP-1 analogues market is witnessing rapid growth as the nation's high obesity prevalence and increased emphasis on weight loss drive demand for obesity treatment in addition to diabetes management
These long-term benefits are harder to achieve with GLP-1 medicines alone, as many patients stop using the medications over time. Study limitations and future research The authors highlighted that the study was observational, not a randomised controlled trial
The goal is not to replace GH directly but to amplify your body's natural GH pulses, particularly the large nocturnal pulse that drives recovery and protein synthesis
How common is anxiety as a side effect of tirzepatide
A few commenters indicated that requiring the median, 10th percentile, and 90th percentile allowed amounts in the MRFs may be misleading for patients who would look at this information as a representation of what they would be expected to pay should they receive that item or service at the hospital
There is going to be growing pressure to cover obesity drugs, so this is not an issue that the incoming administration can easily just sidestep, Larry Levitt, EVP for health policy at KFF, told Healthcare Brew
